Ngake Ngakutshela Lokhu, Jurassic Park, IJurassic World Dominion, USam Neill
USam Neill, umlingisi we-"Jurassic Park", kutholakale ukuthi unomdlavuza wegazi
Mashi 2023: Isahluko sokuqala sememori ka-Sam Neill sizoshaqisa kakhulu umuntu owayengenalo ulwazi lwaso ngaphambili. Kuqala ngokuhlekisa ngokwanele: intambo enhle ngendodakazi yakhe u-Elena ebuzwa mayelana nomdlalo kayise.
Izivivinyo zokwelashwa kwamaseli e-CAR T, ukuhlolwa kwe-myeloma eminingi
Ukuhlolwa komtholampilo ekwelapheni kwamaseli e-CAR-T ezigulini ezine-BCMA/TACI-positive ezibuyelwe kabusha kanye/noma i-myeloma eminingi ephikisayo
Isifinyezo esifushane: Ucwaningo lwe-APRIL CAR-T cell therapy yeziguli ezine-BCMA/TACI positive relapse kanye/noma refractory multiple myeloma Incazelo Eningiliziwe: Lena ingalo eyodwa, ilebula evulekile, si.
AZA-JMML-001, Inkampani Celgene Corporation, i-leukemia yengane ye-myelomonocytic, I-NCT02447666, IVidaza
I-Azacitidine igunyazwe yi-FDA nge-leukemia yentsha ye-myelomonocytic esanda kutholwa
Juni 2022: I-FDA igunyaze umuthi i-azacitidine (Vidaza, Celgene Corp.) wezingane ezine-juvenile myelomonocytic leukemia (JMML) esanda kutholwa. I-pharmacokinetics, i-pharmacodynamics, ukuphepha, nomsebenzi we-azacitidine p.
I-BCMA, I-CARYKTI, i-ciltacabtagene autoleucel, i-ejenti ye-immunomodulatory, Janssen Biotech, i-proteasome inhibitor
I-Ciltacabtagene autoleucel igunyazelwe i-myeloma eminingi ebuyele emuva noma ephikisayo
Mashi 2022: Ngemva kwemigqa yokwelapha emine noma ngaphezulu yangaphambili, okuhlanganisa i-proteasome inhibitor (PI), i-immunomodulatory agent (IMiD), kanye ne-anti-CD38 monoclonal antibody, i-Food and Drug Administration igunyaze i-ciltacabtagene au.
Ucwaningo luphakamisa ukuthi i-CAR T-Cell therapy isebenza ngempumelelo njengomugqa wokuqala wokwelashwa kwe-B-cell lymphoma enkulu engozini
Mashi 2022: Abacwaningi base-University of Texas MD Anderson Cancer Centre bathola ukuthi i-axi-cel, i-autologous anti-CD19 chimeric antigen receptor (CAR T-cell therapy), iyindlela yokwelapha ephephile nesebenzayo yomugqa wokuqala ezigulini ezinezimo eziphuthumayo.
I-Burkitt lymphoma, I-Burkitt-like lymphoma, I-DLBCL, I-Genentech, I-Rituxan, I-Rituximab
I-Rituximab plus chemotherapy igunyazwe yi-FDA ngezinkomba zomdlavuza wezingane
Mashi 2022: I-Food and Drug Administration igunyaze i-rituximab (Rituxan, Genentech, Inc.) ngokuhlanganyela ne-chemotherapy ye-CD20-positive diffuse big-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma.
Amgen, i-carfilzomib, I-Darzalex Faspro, dexamethasone, Janssen Biotech, I-Kyprolis, i-myeloma eminingi
I-Darzalex faspro, i-kyprolis, ne-dexamethasone igunyazwe yi-FDA nge-myeloma eminingi
Mashi 2022: I-Daratumumab + hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) kanye ne-carfilzomib (Kyprolis, Amgen, Inc.) kanye ne-dexamethasone kugunyazwe i-Food and Drug Administration ezigulini ezikhulile ezine-relap.
Ukusebenza kokwelashwa kwe-CAR T-Cell ngokumelene nengozi enkulu ye-B-Cell lymphoma enkulu
Disemba 2020: Abacwaningi base-University of Texas MD Anderson Cancer Centre bathole ukuthi i-axi-cel, i-autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, iyindlela yokwelapha yomugqa wokuqala ephephile futhi esebenzayo yeziguli ezine ...
I-Asciminib, I-leukemia ye-myeloid engapheli, I-Novartis AG, Ph+ CML, I-chromosome ye-Philadelphia, Scemblix
I-Asciminib igunyazelwe i-Philadelphia chromosome-positive chronic myeloid leukemia
Nov 2021: I-Asciminib (Scemblix, Novartis AG) yanikezwa ukugunyazwa okusheshisiwe yi-Food and Drug Administration ezigulini ezine-Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) esigabeni esingamahlalakhona (CP) ebesine-pr.
IBHOLA, I-Brexucabtagene autoleucel, IKite Pharma, UTecartus, ZUMA-3
I-Brexucabtagene autoleucel igunyazwe yi-FDA ngokubuyela emuva noma i-refractory B-cell precursor acute lymphoblastic leukemia
Okthoba 2021: I-Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) igunyazwe i-Food and Drug Administration ezigulini ezikhulile ezine-B-cell precursor acute lymphoblastic leukemia (YONKE). Nge..